Related references
Note: Only part of the references are listed.Molecular mechanisms of drug resistance and its reversal in cancer
Melis Kartal-Yandim et al.
CRITICAL REVIEWS IN BIOTECHNOLOGY (2016)
Global surveillance of cancer survival 1995-2009: analysis of individual data for 25 676 887 patients from 279 population-based registries in 67 countries (CONCORD-2)
Claudia Allemani et al.
LANCET (2015)
Known and putative mechanisms of resistance to EGFR targeted therapies in NSCLC patients with EGFR mutations-a review
Erin L. Stewart et al.
TRANSLATIONAL LUNG CANCER RESEARCH (2015)
Hypoxia Increases Gefitinib-Resistant Lung Cancer Stem Cells through the Activation of Insulin-Like Growth Factor 1 Receptor
Akiko Murakami et al.
PLOS ONE (2014)
Molecular pathways and therapeutic targets in lung cancer
Emma Shtivelman et al.
ONCOTARGET (2014)
An open investigation of the reproducibility of cancer biology research
Timothy M. Errington et al.
ELIFE (2014)
EGFR-TKI Resistance Due to BIM Polymorphism Can Be Circumvented in Combination with HDAC Inhibition
Takayuki Nakagawa et al.
CANCER RESEARCH (2013)
The HDAC inhibitor, MPT0E028, enhances erlotinib-induced cell death in EGFR-TKI-resistant NSCLC cells
M-C Chen et al.
CELL DEATH & DISEASE (2013)
A mechanism of resistance to gefitinib mediated by cellular reprogramming and the acquisition of an FGF2-FGFR1 autocrine growth loop
K. E. Ware et al.
ONCOGENESIS (2013)
Tumor heterogeneity: evolution through space and time in EGFR mutant non small cell lung cancer patients
Margarita Majem et al.
TRANSLATIONAL LUNG CANCER RESEARCH (2013)
Intratumor Heterogeneity: Evolution through Space and Time
Charles Swanton
CANCER RESEARCH (2012)
EGFR mutations in circulating tumour DNA
Rafael Rosell et al.
LANCET ONCOLOGY (2012)
Targeting EGFR in non-small-cell lung cancer: Lessons, experiences, strategies
Giulia M. Stella et al.
RESPIRATORY MEDICINE (2012)
KRAS-mutated non-small cell lung cancer cells are responsive to either co-treatment with erlotinib or gefitinib and histone deacetylase inhibitors or single treatment with lapatinib
Ina Kurtze et al.
ONCOLOGY REPORTS (2011)
Biochemical Mechanisms of Resistance to Small-Molecule Protein Kinase Inhibitors
Ratika Krishnamurty et al.
ACS CHEMICAL BIOLOGY (2010)
Gefitinib or Chemotherapy for Non-Small-Cell Lung Cancer with Mutated EGFR.
Makoto Maemondo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer
Jeffrey A. Engelman et al.
CLINICAL CANCER RESEARCH (2008)
Acquired resistance to tyrosine kinase inhibitors during cancer therapy
Jeffrey A. Engelman et al.
CURRENT OPINION IN GENETICS & DEVELOPMENT (2008)
First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations
Lecia V. Sequist et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
National survey of non-small cell lung cancer in the United States: Epidemiology, pathology and patterns of care
Alex G. Little et al.
LUNG CANCER (2007)
G*Power 3: A flexible statistical power analysis program for the social, behavioral, and biomedical sciences
Franz Faul et al.
BEHAVIOR RESEARCH METHODS (2007)
Epidermal growth factor receptor mutations in lung cancer
Sreenath V. Sharma et al.
NATURE REVIEWS CANCER (2007)
Anticancer activities of histone deacetylase inhibitors
Jessica E. Bolden et al.
NATURE REVIEWS DRUG DISCOVERY (2006)
'Targeting' the epidermal growth factor receptor tyrosine kinase with gefitinib (Iressa®) in non-small cell lung cancer (NSCLC)
W Pao et al.
SEMINARS IN CANCER BIOLOGY (2004)
EGFR mutations in lung cancer:: Correlation with clinical response to gefitinib therapy
JG Paez et al.
SCIENCE (2004)
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib
TJ Lynch et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Mechanisms of disease: Gene silencing in cancer in association with promoter hypermethylation
JG Herman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Share Paper
